7 completed, 5 active not recruiting, 4 terminated, 3 unknown. 22 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 7, Active not recruiting 5, Terminated 4, Unknown 3, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Stage III Breast Cancer: new trials by email Literature Review of Stage III Breast Cancer trials Research Report on Stage III Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer Fluoroestradiol (18F) - Stage III Breast Cancer | Phase 2 | Recruiting | Asan Medical Center | 85 | 2025-12-24 | 2026-01-02 |
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Chuan Wang | 30 | 2025-10-01 | 2025-08-26 |
| Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Niraparib, Dostarlimab - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 66 | 2021-01-21 | 2026-09-24 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan - Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 88 | 2020-10-09 | 2025-11-10 |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer docetaxel, epirubicin and cyclophosphamide, docetaxel, epirubicin and cyclophosphamide plus endostar - Stage III Breast Cancer | Phase 2 / Phase 3 | Unknown | Hebei Medical University Fourth Hospital | 300 | 2019-08-01 | 2019-08-09 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Acupuncture Pilot Study for Cancer-related Cognitive Function Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2019-07-01 | 2026-08-12 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2018-07-10 | 2021-08-11 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Alisertib, Fulvestrant, Laboratory Biomarker Analysis - Estrogen Receptor Status, HER2/Neu Negative | Phase 2 | Completed | Mayo Clinic | 96 | 2017-07-06 | 2026-09-24 |
| Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Investigational Imaging device, AVB-620 - Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast | Phase 2 | Completed | Avelas Biosciences, Inc. | 92 | 2017-07-05 | 2021-06-11 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA T-DM1, Pertuzumab, Excision of tumor/mastectomy - HER-2 Positive Breast Cancer, Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 164 | 2015-01-01 | 2026-10-02 |
| Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer fluorouracil, capecitabine, cyclophosphamide - Stage II Breast Cancer, Stage III Breast Cancer | Phase 2 | Unknown | Guangxi Medical University | 100 | 2014-06-01 | 2014-04-15 |
| Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin Simvastatin, Doxorubicin/cyclophosphamide - Breast Cancer, Stage I Breast Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 34 | 2014-05-20 | 2024-07-09 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | University of Nebraska | 92 | 2012-12-07 | 2026-06-26 |
| A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer Vorinostat and Tamoxifen - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 | 2011-03-01 | 2013-05-17 |
| Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer Autologous dendritic cell vaccination - Stage II Breast Cancer, Stage III Breast Cancer | Phase 2 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 29 | 2011-02-01 | 2016-05-19 |
| Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer vorinostat, conventional surgery - Breast Cancer, Stage I Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2005-10-01 | 2020-02-19 |
| Capecitabine in Women With Operable Breast Cancer Capecitabine - Invasive Breast Carcinoma, Primary Invasive Breast Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 80 | 2004-09-01 | 2015-11-11 |
Showing 20 of 22. Sign in to see all of them.
Breast Neoplasms (22) · Triple Negative Breast Neoplasms (3) · Carcinoma, Ductal, Breast (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Colorectal Neoplasms (1) · Prostatic Neoplasms (1)
Breast Diseases (22) · Neoplasms (22) · Neoplasms by Site (22) · Skin Diseases (22) · Skin and Connective Tissue Diseases (22) · Adenocarcinoma (1) · Breast Carcinoma In Situ (1) · Carcinoma (1) · Carcinoma in Situ (1) · Carcinoma, Ductal (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Cyclophosphamide (5) · Capecitabine (3) · Doxorubicin (3) · Paclitaxel (3) · Trastuzumab (3) · Epirubicin (2) · Tamoxifen (2) · Vorinostat (2) · pertuzumab (2) · 4-phenylthioandrosta-4,6-diene-3,17-dione (1) · AC protocol (1) · Acupuncture Therapy (1) · Ado-Trastuzumab Emtansine (1) · Anastrozole (1) · Congresses as Topic (1)
Dana-Farber Cancer Institute (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Asan Medical Center (1) · Avelas Biosciences, Inc. (1) · Chuan Wang (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Guangxi Medical University (1) · Hebei Medical University Fourth Hospital (1) · Jonsson Comprehensive Cancer Center (1) · Laura Huppert, MD, BA (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · University of Colorado, Denver (1)
United States (17) · China (2) · South Korea (1) · Spain (1)
Adrienne Waks, MD (2) · Amulya C Yellala, MD (1) · Anthony Elias, M.D (1) · Eric Winer, MD (1) · Erica L. Mayer, MD, MPH (1) · Hyehyun Jeong (1) · Ian Krop, MD, PhD (1) · Ingrid Mayer, MD (1) · Jianlun Liu, MD (1) · Jun Mao, MD, MSCE (1) · Karen Smith, MD, MPH (1) · Laura Huppert, MD (1) · Marta Santisteban, MD, PhD. (1) · Nicholas P McAndrew, MD (1) · Sarika Jain, MD (1)
PMID 24464780, PMID 32060053, PMID 34987618, PMID 36892847, PMID 38300710
P30CA006973 (1), P30CA036727 (1), P30CA060553 (1), R01CA214893 (1), U01CA070095 (1)